目前，我國(guó)老年糖尿病患者的發(fā)病人數(shù)越來越多。GLP-1受體激動(dòng)劑是一類新型作用靶點(diǎn)的降糖藥物。新型長(zhǎng)效GLP-1受體激動(dòng)劑度拉糖肽具有改善血糖水平、降低患者體質(zhì)量、每周注射1次的臨床應(yīng)用特點(diǎn)，同時(shí)該藥物也具有胃腸道不適等相關(guān)的不良反應(yīng)。對(duì)度拉糖肽在臨床研究中的應(yīng)用現(xiàn)狀進(jìn)行綜述，供臨床醫(yī)生參考。

At present, the number of older patients with diabetes is increasing in China. GLP-1 receptor agonist is a new kind of antihyperglycemic medication. The new long-acting GLP-1 receptor agonist, dulaglutide, has been shown to control the blood glucose level, reduce the bodyweight of patients, and has been injected once a week in clinical practice. Meanwhile, the drug has also been associated with gastrointestinal discomfort and other adverse reactions. The current situation of the application of dulaglutide in clinic is reviewed in this paper, and provide reference for clinicians.

R977

天津市"131"創(chuàng)新型人才培養(yǎng)工程項(xiàng)目